05 Mar

Posted at 18:13h in COVID-19, Employee Benefits by . .

Legal Update Header On Feb. 26, 2021, the Departments of Labor, Health and Human Services (HHS), and the Treasury issued FAQ guidance to clarify health coverage requirements related to COVID-19.

Coverage of COVID-19 Diagnostic Testing

Health plans and issuers must cover COVID-19 diagnostic items and services without cost-sharing. The FAQs explain that plans and issuers:

05 Mar

Posted at 18:08h in COVID-19, Employee Benefits by . .

After you’ve received your COVID-19 vaccination, it’s normal to wonder what’s next.

Many questions exist, such as whether you can contract COVID-19 again, what safety precautions you should continue and when life might go back to normal. While a COVID-19 vaccination is a critical step toward returning to a sense of normalcy, it’s important to continue to prioritize the safety of yourself and those around you.

05 Mar

Posted at 17:54h in COVID-19, Employee Benefits by . .

News Brief header The White House recently announced that drugmaker Merck & Co., will help produce competitor Johnson & Johnson’s COVID-19 vaccine to expand its production and supply.

President Joe Biden’s administration will play a key role in this partnership. The administration has invoked the Defense Production Act to get two Merck facilities up to the standards necessary to safely manufacture the Johnson & Johnson vaccine. While it will take months to fully equip these plants, Merck has extensive experience and capacity as a vaccine producer and is prepared to use these two facilities to vastly increase supply.  

05 Mar

Posted at 17:41h in COVID-19, Employee Benefits by . .

News Brief header The U.S. Food and Drug Administration (FDA) recently issued an Emergency Use Authorization (EUA) for Johnson & Johnson’s COVID-19 vaccine to be distributed in the United States for use by individuals 18 years of age and older.

This authorization follows a recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) to issue a EUA for the vaccine, and confirms that Americans will have access to a third effective coronavirus vaccine that will allow states to increase distribution.